COSCIENS Biopharma's Announcement of Management Cease Trade Order
COSCIENS Biopharma Inc. (NASDAQ: CSCI) has made a significant announcement regarding the receipt of a management cease trade order (MCTO). This comes as the company acknowledges a potential delay in filing critical financial documents.
Understanding the Management Cease Trade Order
The Ontario Securities Commission (OSC) has accepted COSCIENS' application for the MCTO, which became effective as of April 1, 2025. The order is primarily linked to the delays in filing the annual financial statements for the years ending December 31, 2024, 2023, and 2022, along with other related documents.
Why the Delay?
COSCIENS has confirmed the inability to meet the March 31, 2025, deadline due to several factors, which were previously outlined in a Default Announcement. The company is currently working closely with its auditors to finalize the required filings and anticipates that these will be available shortly, no later than April 7, 2025.
Company Updates and Future Expectations
While the MCTO restricts trading of securities by certain company executives, it will not affect the trading activities of ordinary shareholders. Until the required documents are filed, COSCIENS has pledged to comply with the alternative information guidelines set by the OSC, which includes regular updates via news releases.
Impact on Nasdaq Listing
Importantly, the current situation with the MCTO will not have an immediate impact on COSCIENS’ common shares listed on the Nasdaq Capital Market. The company plans to submit the necessary Form 20-F promptly, though it cannot guarantee a specific filing date.
About COSCIENS Biopharma Inc.
COSCIENS is a renowned life science company resulting from the merger of Aeterna Zentaris and Ceapro Inc. The firm focuses on developing a diverse array of cosmeceutical, nutraceutical, and pharmaceutical products, particularly leveraging proprietary extraction technologies from renewable plant resources. Notable ingredients include oat beta glucan and avenanthramides, which are integral to leading skincare brands.
Continuous Commitment
The leadership at COSCIENS remains dedicated to ensuring clarity and prompt communication with stakeholders regarding its developments, especially concerning its financial filings and compliance with regulatory standards.
Investor Relations and Contact Information
For any questions or concerns, Gilles R. Gagnon, the President & CEO, is available for contact at +1 (780) 421-4555 or via email at ggagnon@cosciensbio.com. Additionally, investors can reach out to Jenene Thomas of the JTC Team at +1 (908) 824-0775 or through csci@jtcir.com.
Frequently Asked Questions
What is the Management Cease Trade Order (MCTO)?
The MCTO is an order issued by the OSC that restricts certain executives from trading the company’s securities until the required filings are submitted.
What caused the delay in financial filings?
COSCIENS has not specified the exact reasons for the delay but has indicated that they are working with auditors to finalize the documents.
How will this affect shareholders?
While executives are restricted from trading, regular shareholders can continue to trade their securities without any restrictions.
When does COSCIENS expect to file the required documents?
The company aims to file the necessary documents by April 7, 2025, at the latest.
What should investors do during this period?
Investors should stay informed through COSCIENS’ regular updates and reports to ensure they are aware of any developments.
